Danielle DiCara | Scientist 4

Danielle DiCara, Scientist 4, Genentech

I completed my BA in Natural Sciences at the University of Cambridge and obtained my PhD at
the Centre for Tumour Biology at Queen Mary University of London. Following post-doctoral work at the Centre for Experimental Medicine & Rheumatology (WHRI, London) and University of Cambridge Department of Oncology I joined the Antibody Engineering department at Genentech.  My research interests focus on molecule targeting for therapeutic and/or diagnostic purposes, with an emphasis on LM design, selection and engineering.


Festival of Biologics Day 1 @ 16:30

Expanding targetability of solid tumors by engineering selectivity for coexpression of two tumor-associated antigens

Safe and effective T Cell Engager (TCE) development for solid tumors is extremely challenging, and it is highly desirable to expand the list of suitable target antigens as well as to increase the precision with which a TCE is able to differentiate between tumor and healthy tissues.  I will present a strategy to improve on-target, off-tumor TCE selectivity by requiring simultaneous engagement of two tumor-associated antigens.  I will also describe the identification of Ly6E and B7H4 as a pair of antigens applicable to this approach, and development of trispecific antibodies selective for Ly6E & B7H4 co-expression.

last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers